This paper quantifies the prevalence of opportunistic prostate cancer screening in New Zealand in 2008
02 October 2010
- Prostate cancer is the commonest malignancy (apart from skin cancer) affecting men in New Zealand, with more than 2,400 men registered with this cancer in 2005.
- The rate of registration of prostate cancer has approximately trebled since 1990.
- This project was undertaken to describe the prevalence of, and factors associated with, opportunistic screening for prostate cancer using PSA tests in primary care in New Zealand.
- Male participants aged 40 to 74 years old were randomly selected from the general electoral rolls.
- The samples were weighted towards Maori participants.
- In addition to ever having had a PSA test, four further PSA test outcome variables covering 2time periods (2008, or 2003-2007) were collected.
- The consent rate was 78% in non-Maori men and 73% in Maori men.
- 49% of participants had ever had a PSA test.
- 18% of participants had a screening PSA test (without LUTS) in primary care in 2008 and
- 22% had had a screening PSA test (without LUTS) in the previous 5 years.
- Most PSA tests taken in primary care were taken in asymptomatic men.
- 50% of non-Maori participants had ever had a PSA test compared to 47% of Maori.
- 29% of Maori participants and 21% of non-Maori men reported visiting a doctor because of urological symptoms between 2003 and 2008.
- 67% of Maori men in the Southern region reported a previous PSA test; significantly morethan other THAs.